Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Distribution and frequency of tyrosine kinase inhibitor-associated long-term complications in children with chronic myeloid leukemia

Distribution and frequency of tyrosine kinase inhibitor-associated long-term complications in children with chronic myeloid leukemia
Dong EE et al. Pediatr Blood Cancer, May 2022 (epub ahead of print)

Link to full abstract

 

 

 

Discontinuation of tyrosine kinase inhibitors in pediatrc chronic myeloid leukemia (Shima H et al. Pediatr Blood Cancer, April 2022)

Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia
Shima H et al. Pediatr Blood Cancer, April 2022 (epub ahead of print)

Link to full abstract

 

 

 

Skin and soft tissue infections in adolescent chronic myeloid leukemia under dasatanib treatment (Uchida E et al. Pediatr Blood Cancer, April 2022)

Skin and soft tissue infections in adolescent chronic myeloid leukemia under dasatinib treatment
Uchida E et al. Pediatr Blood Cancer, April 2022 (epub ahead of print)

 

Prognostic factors for outcomes of allogeneic HSCT for children and adolescents/young adults with CML in the TKI era (Shimada H et al. Transplant Cell Ther, April 2022)

Prognostic factors for outcomes of allogeneic HSCT for children and adolescents/young adults with CML in the TKI era
Shimada H et al. Transplant Cell Ther, April 2022 (epub ahead of print)

 

Therapeutic leukapharesis in pediatric leukemia: Utilization trend and early outcomes in a US Nationwide Cohort (Takahashi T et cl. J Pediatr Hematol Oncol, March 2022)

Therapeutic leukapharesis in pediatric leukemia: Utilization trend and early outcomes in a US Nationwide Cohort
Takahashi T et cl. J Pediatr Hematol Oncol, March 2022

Link to full abstract

 

 

  1. Design and stability of pediatric oral formulation of imatinib (Hinterlang M et al. J Oncol Pharm Pract, March 2022)
  2. Physician risk perceptions and surveillance practices for tyrosine kinase inhibitor long-term effects in pediatric CML (Smith SM et al. Pediatr Hematol Oncol, December 2021)
  3. Comparison of the transcriptomic signature in pediatric and adult CML (Youn M et al. Cancers(Basel), December 2021)
  4. Efficacy of ponatinib prior to and after allogeneic hematopoietic stem cell transplantation in an adolescent with chronic myeloid leukemia in blast phase (Lee JW et al. Blood Res, November 2021)